You have no items in your shopping cart.
Saxenda is indicated as an adjunct to a low-calorie diet and increased physical activity for long-term use in order to correct body weight in adult patients with BMI: ≥30 kg / m2 (obesity) or ≥27 kg / m2 to <30 kg / m2 (excessive body weight) in the presence of at least one concomitant disease associated with overweight, such as prediabetes, type 2 diabetes mellitus, arterial hypertension, dyslipidemia or obstructive sleep apnea syndrome, and Saxenda can be used as an adjunct to a healthy diet and increased physical activity to correct body weight in adolescents aged 12 years and older with a body weight of over 60 kg and obesity (BMI corresponding to ≥30 kg / m2 (obesity) for adults according to international thresholds).
Hypersensitivity to liraglutide or any of the excipients of the drug; history of medullary thyroid cancer, including family history; multiple endocrine neoplasia type 2; severe depression, suicidal thoughts or behavior, including a history. The use is contraindicated in the following groups of patients and in the following conditions / diseases due to the lack of data on efficacy and safety: severe renal failure (creatinine clearance (CC) less than 30 ml / min); severe liver failure; children under 12 years of age; adolescents aged 12 to 18 years with a body weight less than or equal to 60 kg; in patients aged ≥75 years; the period of pregnancy and breastfeeding; chronic heart failure (CHF) IV functional class (in accordance with the NYHA classification (New York Heart Association)); the simultaneous use of other drugs to correct body weight; use in combination with other GLP-1 receptor agonists; secondary obesity due to endocrinological diseases or eating disorders, or against the background of the use of drugs that can lead to weight gain. In patients with diabetes mellitus, Saxenda should not be used as an insulin substitute. The experience of using Saxenda in patients with inflammatory bowel diseases and diabetic paresis of the stomach is limited. The use of liraglutide in these patients is not recommended because it is associated with transient gastrointestinal (GI) adverse reactions, including nausea, vomiting, and diarrhea.
Saxenda is recommended to be used with caution in patients with mild and moderate hepatic insufficiency, thyroid diseases and a history of acute pancreatitis.
Method of administration and dosage:
Saxenda is intended for subcutaneous administration only. It cannot be administered intravenously or intramuscularly. Saxenda is administered once a day at any time, regardless of food intake. It should be injected into the abdomen, thigh, or shoulder area. The place and time of the injection can be changed without dose adjustment. However, it is advisable to inject at approximately the same time of day after choosing the most convenient time. The starting dose is 0.6 mg per day. The dose is increased to 3.0 mg per day, adding 0.6 mg at intervals of at least one week to improve gastrointestinal tolerance. Therapy with Saxenda for adult patients should be discontinued if, after 12 weeks of using the drug at a dose of 3.0 mg per day, the loss in body weight is less than 5% of the initial value. Therapy with Saxenda for adolescents aged 12 years and older should be discontinued and reviewed if, after 12 weeks of using the drug at a dose of 3.0 mg per day or the maximum tolerated dose, patients have lost less than 4% of their BMI or BMI z-score.
Gastrointestinal disorders were the most frequently reported side effects during Saxenda therapy.
Package quantity: 1 piece
Volume: 3 ml
Expiration date: 30 months
Storage conditions: Avoid freezing